The appraisal committee (see section 6) considered evidence submitted by Pfizer and a review of this submission by the evidence review group (ERG). This appraisal was a Cancer Drugs Fund reconsideration of the published NICE technology appraisal guidance on bosutinib for previously treated chronic myeloid leukaemia. It focused on cost-effectiveness analyses using a revised patient access scheme, which provides a simple discount to the list price of bosutinib. The level of the discount is commercial in confidence. See the committee papers for full details of the Cancer Drugs Fund reconsideration evidence and the history for full details of the evidence used for NICE's original technology appraisal guidance on bosutinib.